Introduction
Down syndrome is the most commonest chromosomal abnormality in live-born infants 1,2 and the most commonest congenital cause of intellectual disability. 3 Various screening strategies have been introduced over the years with the aim of offering prospective parents the ability to make informed decisions. The impact of screening has generally been less than that predicted by modelling studies. 4, 5 Other temporal trends, particularly changes in birth rate and maternal age profile, are also likely to have an influence on the live birth rate of Down syndrome. Survival of infants with Down syndrome has improved because of better care (especially of cardiovascular malformations) and survival into mid or late adult life is now expected. Few adults with Down syndrome are likely to be capable of unsupported independent existence. Any change in the birth prevalence and survival of Down syndrome will have implications for the provision of long-term care of children and adults with this condition.
Screening and prenatal diagnosis were recommended in the United Kingdom by the Royal College of Obstetrics and Gynaecology in 1993. Screening strategies in the northern region varied during the study period -serum screening was first used in a pilot project in two health districts in 1988 and was introduced across the region in 1991. Maternity units responsible for about 50% of deliveries offered screening to all pregnant women, regardless of age, since 1992. The remaining units offered amniocentesis on an age-related basis. In 1997 -2000, two of these units, responsible for about 8% of deliveries, began to offer serum screening to all mothers. Thus, by 2000, serum screening was available to nearly 60% of mothers in this region. In the study area, it would appear that where serum screening for trisomy 21 is offered regardless of age, it is taken up by about 50% of women.
This study was performed to assess trends in the prevalence at live birth of Down syndrome in 1985 -2004 in one health region of the United Kingdom. We also looked at trends in survival to 1 year in infants with Down syndrome with and without cardiac defects.
Methods
We based this study on the former Northern Health Region of England. The resident population is around three million with a recent average birth rate of around 35 000 per year. For the years in question (1 January 1985 to 31 December 2004), we obtained details of all live births and live births of infants with Down syndrome confirmed by karyotype (with no upper age limit at diagnosis) from the Northern Congenital Abnormality Survey (NorCAS). NorCAS has collected data on all chromosomal abnormalities and all congenital malformations in this population since 1985. 6 NorCAS is a member of the EUROCAT network of population-based registries for surveillance of congenital abnormalities and follows EUROCAT methodology. 7 The
Northern Genetics Service, Newcastle Hospitals NHS Foundation Trust, provided data on the uptake of maternal serum screening, chorionic villus biopsy and amniocentesis. We obtained details of terminations of pregnancy because of Down syndrome in the region from NorCAS. The Regional Paediatric Cardiology Database provided data on cardiovascular malformations associated with Down syndrome. 8 Cases were checked against the Regional Perinatal Mortality Survey to confirm the survival to 1 year. 9 The
Office for National Statistics provided maternal age data for our local population. We included all cases where pregnancy reached at least 24 weeks and all terminations for fetal abnormality. Spontaneous losses before 24 weeks were noted separately but were not included in the figures for analysis because only a small and variable proportion of such losses are subjected to chromosomal analysis. 6 
Statistical analysis
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In the 20 years of our study, Down syndrome affected 1188 pregnancies which either reached 24 weeks gestation or were terminated for fetal abnormality. The prevalence increased from 1.3 to 2.5 per 1000 total births. (Figure 3 ) Poisson regression analysis showed that the temporal trend in birth prevalence was highly significant (Po0.0001). Chromosomal analysis showed trisomy 21 in 1114, mosaicism in 30, translocation in 41, trisomy 21 plus XYY karyotype in two and trisomy 21 plus XXY karyotype in one. Down syndrome was also noted in 61 first trimester losses (not included in further analysis).
An antenatal diagnosis was made in 477/1188 cases (40%, 95% CI 37 -43%) and was followed by termination of pregnancy in 389 (81%), stillbirth in 17 (4%) and live birth in 71 (15%). The decision to terminate the pregnancy after antenatal diagnosis varied with maternal age. The termination rate was 50/85 (59%, 95% CI 48 -69%) for mothers aged less than 30 years, and 339/393 (86%, 95% CI 83 -89%) aged 30 and above (w 2 ¼ 34.7, Po0.0001).
Antenatal diagnosis was made in 17/51 stillbirths (33%) and 71/748 live births (9%). Antenatal diagnosis was made at a median gestation of 17 weeks (mean: 16, range: 10 -24) in pregnancies ending in termination and at a median gestation of 20 weeks (mean: 23, range: 11 -38) in pregnancies resulting in live birth.
There were 748 live births (63%, 95%CI 60 -66%) with Down syndrome (mean 1.08 per 1000 live births over 20 years). The live birth prevalence of Down syndrome declined from 1. 
Maternal age
The proportion of mothers of all live-born infants in the population who were 35 years or above at delivery rose from 6 to 15% over 20 years (Figure 1 ). The proportion of mothers who were 35 years or above in Down syndrome pregnancies was 30% in 1985 -1989, 33% in 1990 -1994, 44% in 1995 -1999 
Discussion
This study has shown complex changes over time in births with Down syndrome within a population. The total number of Down syndrome pregnancies is increasing, probably due mainly to the increasing proportion of older 
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C Irving et al mothers. Live births with Down syndrome declined in the first half of our study, probably as a result of the introduction of serum screening and termination of pregnancy. In the second half of our study, live births with Down syndrome increased and infant mortality decreased, so there was an increase in long-term survivors. It seems likely that the influence of increasing maternal age outweighed the effect of antenatal diagnosis and termination of pregnancy in the second 10 years. Our study represents a population with high ascertainment of Down syndrome pregnancies in comparison with other registries. 5 Local data have been shown to have better ascertainment than the England and Wales national database. 10 Another strength of this study is that we have data on the local uptake of maternal serum screening and amniocentesis. To our knowledge, Gidiri et al 5 provide the only other UK data on the uptake of maternal serum screening, and they found a large reduction in the uptake over a similar time period. We did not find such a trend, but rather a plateau in the uptake, to a similar level of around 40%. This suggests that over the last 20 years, there have been wide regional variations in the uptake of maternal serum screening as well as trends over time. One factor relevant to the uptake but for which we do not have sufficient information to analyse is the nature of pretest counselling, and there have been recent efforts to standardise this as part of the National Health Service fetal anomaly screening programme (http://nscfa.web.its. manchester.ac.uk).
A further strength of our study is the inclusion of recent data on survival to one year. Rasmussen et al 11 reported
survival to 1 year in Atlanta between 1979 and 1998 to be 92.9% -comparable to our results. They had similar results with respect to the effect of cardiovascular malformations on survival to 1 year but do not provide data in trends in these factors over time. How do our findings relate to those from other studies? Our study was based on the population of Northern England which is 97% white European. The proportion of mothers aged 35 or more years is about 2% lower than in the rest of England and Wales, 12 so elsewhere the influence of maternal age may be greater than we have observed. During most of the period under study, the availability of maternal serum screening was variable due to local variation in funding decisions. In 2001, the UK National Screening Committee was given responsibility to ensure a national programme was implemented in England by 2005. (www.screening.nhs.uk) Standardisation was therefore achieved in the Northern region of England after completion of this audit. The uptake of maternal serum screening in our region remains lower than in some others. In East Gloucestershire uptake, declined from 66 to 47% during the 1990s 13 There was wide variation in the rate of termination in the face of an antenatal diagnosis from 0 -77%. Despite an increase in pregnancies with Down syndrome, the increase in terminations of pregnancy over time led to a stable or slightly reduced prevalence at live birth of Down syndrome. We have shown that the termination rate after prenatal diagnosis was lower in mothers younger than 30 years. Prenatal diagnosis in the younger mothers was more likely to have been based on ultrasound diagnosis of malformations with later karyotyping and therefore diagnosis of Down syndrome may have been made at a later gestation than for older mothers having an invasive test performed early. Our report covers a later time frame than these published reports. We have perhaps a lower detection rate and a continuing rise in the proportion of older mothers. It may be that other populations will in time also show a net increase in live births with Down syndrome if maternal age continues to rise. A recent study from The Netherlands reports a live birth prevalence of Down syndrome in 2003 of 1.6 per 1000. 18 Another recent report, on births in 1986 -2004 in Australia, showed a slower rate of increase in total Down syndrome births than our series (with a slower increase in older mothers) and a fall in affected live births, so patterns vary in different populations. 19 The increased use of nuchal translucency screening may contribute to a future decline in live births with Down syndrome, as has been documented recently in Denmark. 20 The recent suggestions for improvement in antenatal counselling may also influence the uptake rates for screening. Survival of infants with Down syndrome continues to improve. 18, 21 In our recent experience, infant survival after live birth is now close to 100%. This is partly due to better surgical management of gastrointestinal and cardiovascular malformations. Long-term survival is also improving, and the large majority of people with Down syndrome are now expected to live well into adult life. 22 Of those born 40 years ago, 75% now live to 40 and it is likely that the longterm survival of those born now will be much higher. Our data show an increasing number of infant survivors with Down syndrome over the last 10 years. Whatever future developments may occur in screening and whatever the resultant effect on live birth, there is currently a growing cohort of survivors with Down syndrome. In the long term, they have their own specific health problems, which are not well met by general resources for health care. 23 In particular, adults with Down syndrome have an increased risk of endocrine, haematological, respiratory, neurological, psychiatric and social problems, which may require extra screening as well as extra health care resources. The current increasing number of children with Down syndrome will require adequate provision of health care throughout childhood and adult life.
